omeprazole has been researched along with Autoimmune Diabetes in 7 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty nine patients with type 1 diabetes mellitus and H." | 2.69 | Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. ( Aller, R; Boixeda de Miquel, D; de la Calle, H; de Luis, DA; Garcia Avello, A; Lasuncion, MA; Martin de Argila, C, 1999) |
| " pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently." | 2.69 | Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. ( Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000) |
| "A diagnosis of toxic epidermal necrolysis (TEN) was made." | 2.45 | Toxic epidermal necrolysis and neutropaenia: complications of omeprazole. ( Burke, A; Burns, A; Handfield-Jones, S; Palmer, M; Sinha, A; Thakor, AS, 2009) |
| "The study included 100 youth with type 1 diabetes and seropositive for Hp (European Caucasians: n=49; Moghrabin Caucasians: n=51)." | 1.34 | [Helicobacter pylori infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes]. ( Dorchy, H; Khalil, T; Melot, C; Scaillon, M, 2007) |
| "pylori in children with type 1 diabetes mellitus improves their metabolic control." | 1.32 | Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. ( Cammarota, G; Candelli, M; Crea, F; Gasbarrini, A; Gasbarrini, G; Marietti, G; Nista, EC; Petrucci, S; Pignataro, G; Rigante, D; Schiavino, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lagunas-Rangel, FA | 1 |
| Koshelev, D | 1 |
| Nedorubov, A | 1 |
| Kosheleva, L | 1 |
| Trukhan, V | 1 |
| Rabinovitch, A | 1 |
| Schiöth, HB | 1 |
| Levit, S | 1 |
| Thakor, AS | 1 |
| Burke, A | 1 |
| Handfield-Jones, S | 1 |
| Sinha, A | 1 |
| Palmer, M | 1 |
| Burns, A | 1 |
| Candelli, M | 1 |
| Rigante, D | 1 |
| Marietti, G | 1 |
| Nista, EC | 1 |
| Crea, F | 1 |
| Schiavino, A | 1 |
| Cammarota, G | 1 |
| Pignataro, G | 1 |
| Petrucci, S | 1 |
| Gasbarrini, G | 2 |
| Gasbarrini, A | 2 |
| Khalil, T | 1 |
| Dorchy, H | 1 |
| Scaillon, M | 1 |
| Melot, C | 1 |
| de Luis, DA | 2 |
| Garcia Avello, A | 1 |
| Lasuncion, MA | 1 |
| Aller, R | 2 |
| Martin de Argila, C | 1 |
| Boixeda de Miquel, D | 1 |
| de la Calle, H | 2 |
| Ojetti, V | 1 |
| Pitocco, D | 1 |
| Armuzzi, A | 1 |
| Silveri, NG | 1 |
| Pola, P | 1 |
| Ghirlanda, G | 1 |
| Cordero, JM | 1 |
| Caballero, C | 1 |
| Boixeda, D | 1 |
| Cantón, R | 1 |
1 review available for omeprazole and Autoimmune Diabetes
| Article | Year |
|---|---|
Toxic epidermal necrolysis and neutropaenia: complications of omeprazole.
Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Combined Modality Therapy; Diabetes Mellitus, Type 1; Di | 2009 |
2 trials available for omeprazole and Autoimmune Diabetes
| Article | Year |
|---|---|
Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients.
Topics: Adult; Amoxicillin; Analysis of Variance; Body Mass Index; Breath Tests; Cholesterol; Clarithromycin | 1999 |
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bism | 2000 |
4 other studies available for omeprazole and Autoimmune Diabetes
| Article | Year |
|---|---|
Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice.
Topics: Animals; C-Peptide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase | 2022 |
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benz | 2004 |
[Helicobacter pylori infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes].
Topics: Adolescent; Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulce | 2007 |
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus.
Topics: Adult; Aged; Amoxicillin; Antibodies, Bacterial; Blood Glucose; Clarithromycin; Diabetes Mellitus, T | 2001 |